Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Castration-resistant metastatic prostate cancer: current status and treatment possibilities.

Carles J, Castellano D, Climent MÁ, Maroto P, Medina R, Alcaraz A.

Clin Transl Oncol. 2012 Mar;14(3):169-76. doi: 10.1007/s12094-012-0780-8. Review.

PMID:
22374419
2.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
3.

[Castration-resistant prostate cancer: where are we going?].

Alcaraz A, Medina R, Maroto P, Climent MÁ, Castellano D, Carles J.

Actas Urol Esp. 2012 Jun;36(6):367-74. doi: 10.1016/j.acuro.2011.10.010. Epub 2011 Dec 19. Review. Spanish.

PMID:
22188754
4.

SEOM clinical guidelines for treatment of prostate cancer.

Arranz Arija JÁ, Cassinello Espinosa J, Climent Durán MÁ, Rivero Herrero F; SEOM (Spanish Society of Clinical Oncology).

Clin Transl Oncol. 2012 Jul;14(7):520-7.

PMID:
22721797
5.

New therapeutic strategies for castration-resistant prostate cancer.

Tanaka T, Nakatani T.

Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):373-83. doi: 10.2174/157489211796957793. Review.

PMID:
21612574
6.

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.

Paller CJ, Antonarakis ES.

Drug Des Devel Ther. 2011 Mar 10;5:117-24. doi: 10.2147/DDDT.S13029. Review. Erratum in: Drug Des Devel Ther. 2011;5:183.

7.

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR.

Eur J Cancer. 2012 Jan;48(1):85-93. doi: 10.1016/j.ejca.2011.10.014. Epub 2011 Nov 28.

PMID:
22129890
8.

[Role of chemotherapy in castration-resistant prostate cancer: are there new approaches?].

De Santis M, Bachner M.

Urologe A. 2012 Jan;51(1):39-43. doi: 10.1007/s00120-011-2739-8. German.

PMID:
22258375
9.

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.

Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ.

Cancer. 2011 Jun 1;117(11):2419-25. doi: 10.1002/cncr.25810. Epub 2010 Dec 29.

10.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
11.

Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.

Bracarda S, Logothetis C, Sternberg CN, Oudard S.

BJU Int. 2011 Apr;107 Suppl 2:13-20. doi: 10.1111/j.1464-410X.2010.10036.x.

12.

Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).

Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, Shariat SF.

BJU Int. 2012 Apr;109(7):968-85. doi: 10.1111/j.1464-410X.2011.10643.x. Epub 2011 Oct 28. Review.

13.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.

Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.

PMID:
20888992
14.

Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.

Gallardo E, Arranz JÁ, Maroto JP, León LÁ, Bellmunt J.

Crit Rev Oncol Hematol. 2013 Nov;88(2):357-67. doi: 10.1016/j.critrevonc.2013.06.008. Epub 2013 Jul 16. Review.

PMID:
23867574
15.

Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer.

Bianchini D, de Bono JS.

Eur J Cancer. 2011 Sep;47 Suppl 3:S189-94. doi: 10.1016/S0959-8049(11)70164-2. Review. No abstract available.

PMID:
21943974
16.

New therapies for castration-resistant prostate cancer: efficacy and safety.

Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.

Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4. Review.

PMID:
21592649
17.

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.

Altavilla A, Iacovelli R, Procopio G, Alesini D, Risi E, Campennì GM, Palazzo A, Cortesi E.

Cancer Biol Ther. 2012 Sep;13(11):1001-8. doi: 10.4161/cbt.21188. Epub 2012 Jul 24. Review.

18.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Eur Urol. 2011 Apr;59(4):572-83. doi: 10.1016/j.eururo.2011.01.025. Epub 2011 Jan 25.

PMID:
21315502
19.

Novel treatments for castration-resistant prostate cancer.

Sternberg CN.

Eur J Cancer. 2011 Sep;47 Suppl 3:S195-9. doi: 10.1016/S0959-8049(11)70165-4. Review.

PMID:
21943975
20.

Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.

Sartor O, Michels RM, Massard C, de Bono JS.

Oncologist. 2011;16(11):1487-97. doi: 10.1634/theoncologist.2010-0412. Epub 2011 Nov 2. Review.

Supplemental Content

Support Center